SGHT · NASDAQ
Sight Sciences, Inc.
$9.43 +0.24 (+2.55%)
Company overview
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients, and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NASDAQ
- Market cap
- $519M
- Employees
- 216
- Headquarters
- Menlo Park, CA
- Website
- sightsciences.com
- CEO
- Paul Badawi
- Listed
- July 15, 2021
- P/E
- -13.31
- Dividend yield
- 0.00%
Company financials
- Revenue
- $79.6M
- Gross profit
- $68.6M
- Operating income
- -$35.7M
- EBITDA
- -$32.5M
- Net income
- -$37.3M
- EPS
- -$0.71
- Total assets
- $110M
- Total debt
- $40.9M
- Gross margin
- 86.17%
- Net margin
- -46.83%
- Earnings yield
- -7.51%
No geographic segmentation.
Showing FY 2025
SGHT
1D
NASDAQ
O9.22H10.06L8.99C9.66+0.24 (+2.55%)Vol575.83K
News